{"id":3206,"text":"These authors contributed equally to this work.","label":[],"Comments":[]}
{"id":3207,"text":"Alpinia officinarum Hance of the Chinese traditional herb for the treatment of emesis, abdominal pain and diarrhea has been used to counteract gastric disease induced by indomethacin in rats without obvious side effects.","label":[[0,26,"Herb name"],[32,40,"Ethnic group"],[78,85,"Pathology"],[87,101,"Pathology"],[106,114,"Pathology"],[143,158,"Pathology"],[170,182,"Drug"],[207,219,"Pathology"]],"Comments":[]}
{"id":3208,"text":"However, the role of herb-drug interaction between indomethacin and A. officinarum based on pharmacokinetic, tissue distribution and excretion still remains unknown.","label":[[50,63,"Drug"],[68,83,"Herb name"]],"Comments":[]}
{"id":3209,"text":"In this study, an ultra-fast liquid-tandem mass spectrometry (UFLC-MS\/MS) method was developed for simultaneous determination of indomethacin and its three metabolites, O-desmethylindomethacin (ODI), deschlorobenzoylindomethacin (NDI) and indomethacin acyl-β-D-glucuronide (IDAβG) by oral administration of indomethacin solution with and without the ethanolic extract of A. officinarum and applied to comparative pharmacokinetic, tissue distribution and excretion studies.","label":[[129,141,"Drug"],[307,319,"Drug"],[350,385,"Extraction process"],[371,386,"Herb name"]],"Comments":[]}
{"id":3210,"text":"Our results clarified that oral administration of A. officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin.","label":[[49,64,"Herb name"],[135,147,"Drug"]],"Comments":[]}
{"id":3211,"text":"And the pharmacokinetic interaction between indomethacin and A. officinarum reduced the systemic exposure of indomethacin and increased its elimination.","label":[[44,57,"Drug"],[61,75,"Herb name"],[109,121,"Drug"]],"Comments":[]}
{"id":3212,"text":"Tissue distribution results demonstrated that co-administration of A. Officinarum could not reduce the accumulation of indomethacin in the target tissue of the stomach, but could accelerate the excretions of indomethacin and its three metabolites including ODI, NDI and IDAβG in the bile and feces of rats in the excretion study.","label":[[67,81,"Herb name"],[119,131,"Drug"],[208,220,"Drug"]],"Comments":[]}
{"id":3213,"text":"Therefore, A. Officinarum might have a gastrointestinal protective effect through the interaction role with indomethacin based on the pharmacokinetics and excretion in rats.","label":[[11,25,"Herb name"]],"Comments":[]}
{"id":3214,"text":"An UFLC-MS\/MS method was developed for simultaneous determination of indomethacin and its metabolites by oral administration of indomethacin with and without A. officinarum Hance and applied to comparative pharmacokinetic, tissue distribution and excretion studies.","label":[[68,81,"Drug"],[127,140,"Drug"],[158,179,"Herb name"]],"Comments":[]}
{"id":3215,"text":"Our results first clarified that oral administration of A. officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin.","label":[[55,70,"Herb name"],[141,153,"Drug"]],"Comments":[]}
{"id":3216,"text":"And the pharmacokinetic interaction between indomethacin and A. officinarum leaded to reduce the systemic exposure of indomethacin and increase its elimination.","label":[[43,56,"Drug"],[61,76,"Herb name"],[118,130,"Drug"]],"Comments":[]}
{"id":3217,"text":"A. Officinarum could accelerate the excretions of indomethacin and its three metabolites in the bile and feces of rats in the excretion study.","label":[[0,14,"Herb name"],[49,62,"Drug"]],"Comments":[]}
{"id":3218,"text":"Therefore, A. Officinarum might be of the gastrointestinal protective effect through the interaction role with indomethacin based on the pharmacokinetics and excretion in rats.","label":[[11,25,"Herb name"],[111,124,"Drug"]],"Comments":[]}
{"id":3219,"text":"Non-steroidal anti-inflammatory drugs (NSAIDs) are widely applied worldwide and used by more than 30 million people every day, accounting for about 60% of OTC market shares of the painkiller in the United States [1].","label":[[0,46,"Drug"]],"Comments":[]}
{"id":3220,"text":"However, adverse reactions in the upper digestive tract, such as gastric ulcer, are always accompanied by therapeutic effects with markedly health risks, and thus the use of NSAIDs is frequently curtailed [[2], [3], [4]].","label":[[9,26,"Pathology"],[173,180,"Drug"]],"Comments":[]}
{"id":3221,"text":"Indomethacin, one of the most effective NSAIDs, is applied to the treatment of reducing fever, pain and swelling but is also harmful to the gastrointestinal tract [[5], [6], [7]].","label":[[0,12,"Drug"],[39,46,"Drug"],[88,93,"Pathology"],[95,99,"Pathology"],[104,112,"Pathology"]],"Comments":[]}
{"id":3222,"text":"Its plasma drug concentration and bioavailability are high and oral absorption is fast; however, cumulative medicinal doses and high plasma drug concentrations would also boost the gastrointestinal side effects of NSAIDs [[8], [9], [10]].","label":[[34,50,"Parameter"],[198,210,"Pathology"],[213,220,"Drug"]],"Comments":[]}
{"id":3223,"text":"Therefore, how to alleviate or eliminate the gastric injury caused by NSAIDs is a huge challenge we are facing.","label":[[45,59,"Pathology"],[70,77,"Drug"]],"Comments":[]}
{"id":3224,"text":"So far, concomitant use of synthetic drugs, such as H2 receptor antagonists, mucosal protective agents and proton pump inhibitors, has been widely employed for relieving side effects of gastrointestinal injuries induced by NSAIDs, thereby reducing mortality and morbidity rates [[11], [12], [13]].","label":[[51,75,"Drug"],[77,102,"Drug"],[107,129,"Drug"],[169,182,"Pathology"],[186,211,"Pathology"],[223,229,"Drug"]],"Comments":[]}
{"id":3225,"text":"However, they are not completely effective and these allopathic medicines may cause undesirable side effects.","label":[[96,108,"Pathology"]],"Comments":[]}
{"id":3226,"text":"It has been reported that these agents may exacerbate NSAID-induced small intestine injury by dysbiosis and further research is needed to prove their safety and effectiveness [14,15].","label":[[54,59,"Drug"],[74,90,"Pathology"],[94,103,"Pathology"]],"Comments":[]}
{"id":3227,"text":"Safety and effectiveness concerns related to NSAIDs have prompted the development of plant-derived drugs.","label":[[45,52,"Drug"]],"Comments":[]}
{"id":3228,"text":"Traditional Chinese medicine from natural products of botanic origin is a promising therapeutic resource with fewer adverse effects in the treatment of the gastrointestinal damage [[16], [17], [18]].","label":[[12,20,"Ethnic group"],[115,131,"Pathology"]],"Comments":[]}
{"id":3229,"text":"Alpinia officinarum Hance of the Zingiberaceae family is a Chinese traditional herb that mainly grows in the south of China.","label":[],"Comments":[]}
{"id":3230,"text":"There is a long history of its use for counteracting emesis, abdominal pain and diarrhea without obvious side effects in Asia.","label":[[52,59,"Pathology"],[61,76,"Pathology"],[79,89,"Pathology"],[105,117,"Pathology"]],"Comments":[]}
{"id":3231,"text":"Therefore, A. officinarum has been considered for the treatment of NSAIDs-induced gastric diseases [[19], [20], [21], [22]].","label":[[10,25,"Herb name"],[67,73,"Drug"]],"Comments":[]}
{"id":3232,"text":"Furthermore, our previous studies have preliminarily demonstrated the antiulcer effect of A. officinarum extract in an ethanol-induced gastrointestinal injury rat model and pharmacological mechanisms in treating indomethacin-induced gastric injury through cyclooxygenase and non-cyclooxygenase pathways [23,24].","label":[[89,104,"Herb name"],[135,158,"Pathology"],[212,224,"Drug"],[233,247,"Pathology"],[256,302,"Target"]],"Comments":[]}
{"id":3233,"text":"However, it is also plausible that the effect of reducing the gastric injury could be due to decreasing system exposure of indomethacin and increasing the excretion of indomethacin and its metabolites after oral administration of A. officinarum extract to rats.","label":[[62,76,"Pathology"],[123,136,"Drug"],[168,181,"Drug"],[230,244,"Herb name"]],"Comments":[]}
{"id":3234,"text":"Researches on antiulcer effects and action mechanisms of A. officinarum induced by indomethacin in rats were previously conducted using molecular biology methods, and further research in terms of pharmacokinetics is necessary to understand the efficacy and safety of A. officinarum.","label":[[57,71,"Herb name"],[83,96,"Drug"],[266,282,"Herb name"]],"Comments":[]}
{"id":3235,"text":"Hence, comparative pharmacokinetic, tissue distribution and excretion studies of indomethacin and its three metabolites were conducted by the oral administration of indomethacin solution with and without the ethanolic extract of A. officinarum to rats to clarify the gastrointestinal protective effect of A. officinarum.","label":[[81,94,"Drug"],[165,178,"Drug"],[208,244,"Extraction process"],[229,243,"Herb name"],[305,319,"Herb name"]],"Comments":[]}
{"id":3236,"text":"A. officinarum Hance was collected from Xuwen County, Guangdong Province of China, in August 2016 and identified by Prof. Jianping Tian of Hainan Medical University, China.","label":[[0,14,"Herb name"]],"Comments":[]}
{"id":3237,"text":"The plant was deposited at the School of Pharmacy of Hainan Medical University (No.","label":[],"Comments":[]}
{"id":3238,"text":"20160716).","label":[],"Comments":[]}
{"id":3239,"text":"The ethanol extract of A. officinarum was prepared based on our previous described methods [24].","label":[[4,37,"Extraction process"],[22,37,"Herb name"]],"Comments":[]}
{"id":3240,"text":"The pulverised rhizomes of A. officinarum (1 kg) were weighed precisely and extracted 3 times under reflux with 8-fold 80% ethanol for 1 h. The combined ethanol extracts were concentrated to 40% and purified with AB-8 macroporous resin by 80% ethanol.","label":[[15,23,"Herb part"],[27,42,"Herb name"]],"Comments":[]}
{"id":3241,"text":"Then, polysaccharides, monosaccharides, and phenolic acids were removed.","label":[],"Comments":[]}
{"id":3242,"text":"Indomethacin (purity 99%, CAS 53-86-1) was purchased from Dalian Meilun Biotechnology Co., Ltd (China).","label":[[0,13,"Drug"]],"Comments":[]}
{"id":3243,"text":"The indomethacin metabolites of O-desmethyl indomethacin (ODI; purity 99%, CAS 2504-32-7) and N-deschlorodenzoyl indomethacin (NDI; purity 99%, CAS 2882-15-7), indomethacin acyl-β-D-glucuronide (IDAβG; purity 99%, CAS 75523-11-4) and internal standard (IS) of indobufen (purity 99%, CAS  Male Sprague-Dawley (SD) rats (Tianqin Biotechnology, Changsha, China), weighing 220–250 g, were housed under a 12 h light\/dark cycle at 25 °C and allowed ad libitum access to water and food.","label":[[4,17,"Drug"]],"Comments":[]}
{"id":3244,"text":"All rat experiments were performed and approved by per International Guidelines for Care and Use of Laboratory Animals and the Animal Ethics Committee of Hainan Medical University (reg.","label":[],"Comments":[]}
{"id":3245,"text":"no.","label":[],"Comments":[]}
{"id":3246,"text":"201506017\/HMU).","label":[],"Comments":[]}
{"id":3247,"text":"All biological samples were analyzed using a Shimadzu LC-20 AD UFLC system (Shimadzu Corp., Tokyo, Japan) coupled to an AB-SCIEX API 4000 plus mass spectrometer (Toronto, Canada) with an electrospray ionization (ESI) source.","label":[],"Comments":[]}
{"id":3248,"text":"The ultra-fast liquid-tandem mass spectrometry (UFLC-MS\/MS) system and data processing were controlled by AB-SCIEX Analyst software.","label":[],"Comments":[]}
{"id":3249,"text":"Prepared biological samples were separated on a Kinetex XB-C All analytes were measured with optimized multiple reaction monitoring (MRM) in the negative ion mode.","label":[],"Comments":[]}
{"id":3250,"text":"The parameters of the ESI (−) mode were selected: curtain gas (CUR) at 50 psi; ion spray voltage at −4.5 kV; nebulizer N Standard stock solutions of indomethacin, ODI, NDI and IDAβG were prepared in methanol at 1.2 mg\/mL.","label":[[149,161,"Drug"]],"Comments":[]}
{"id":3251,"text":"The four stock solutions were pooled with the same volume to produce combined standard working solutions at concentrations of 0.3 mg\/mL for every standard.","label":[],"Comments":[]}
{"id":3252,"text":"IS working solution was diluted with methanol to 4 μg\/mL.","label":[],"Comments":[]}
{"id":3253,"text":"All prepared stock and working solutions were stored at −20 °C prior to use.","label":[],"Comments":[]}
{"id":3254,"text":"Calibration samples were freshly prepared by spiking the appropriate working solutions into the blank matrices (plasma\/tissue homogenates\/bile\/urine\/feces homogenates) to achieve the appropriate final concentrations for indomethacin and its three metabolites in different biological matrices.","label":[[220,233,"Drug"]],"Comments":[]}
{"id":3255,"text":"The QC sample concentrations were also prepared using the same method and stored at −20 °C for whole analysis.","label":[],"Comments":[]}
{"id":3256,"text":"A protein precipitation process was followed for extraction of indomethacin and its metabolites from rat samples (plasma\/tissues\/bile\/urine\/feces).","label":[[63,76,"Drug"]],"Comments":[]}
{"id":3257,"text":"An aliquot of 50 μL plasma diluted 6- and 30-fold step by step using blank rat plasma, respectively, was precipitated with 290 μL methanol-acetonitrile solution (1:1, V\/V) after the addition of 10 μL IS (indobufen, 4 μg\/mL).","label":[],"Comments":[]}
{"id":3258,"text":"The plasma diluted 6-fold was used to analyze the ODI and NDI, and 30-fold diluted plasma was analyzed for indomethacin.","label":[[107,119,"Drug"]],"Comments":[]}
{"id":3259,"text":"Then, the mixtures were vortex-mixed for 10 min at 2000 rpm and centrifuged at 13,000 rpm for 10 min.","label":[],"Comments":[]}
{"id":3260,"text":"Finally, 5 μL of the resultant mixtures were applied for UFLC-MS\/MS analysis.","label":[],"Comments":[]}
{"id":3261,"text":"Tissue samples were homogenized in four parts of ice-cold 0.9% saline solution and then centrifuged at 13000 rpm for 10 min to obtain tissue homogenates.","label":[],"Comments":[]}
{"id":3262,"text":"Tissue homogenates were treated by the same method as plasma sample preparation except dilution process.","label":[],"Comments":[]}
{"id":3263,"text":"And an aliquot of 10 μL urine was precipitated with 70 μL methanol-acetonitrile solution (1:1, V\/V, including 5% formic acid and 80 ng\/mL IS).","label":[],"Comments":[]}
{"id":3264,"text":"After urine sample extraction, it was vortex-mixed for 10 min at 2000 rpm and centrifuged at 13,000 rpm for 10 min.","label":[],"Comments":[]}
{"id":3265,"text":"And then 5 μL supernatants were injected into the UFLC-MS\/MS system to analyze.","label":[],"Comments":[]}
{"id":3266,"text":"Besides, 10 μL of bile samples were mixed with the same volume of 0.5% formic-aqueous solution and then were precipitated with 60 μL methanol-acetonitrile solution (1:1, V\/V, including 0.5% formic acid and 40 ng\/mL IS).","label":[],"Comments":[]}
{"id":3267,"text":"After bile samples were extracted, the same treatment methods with urine samples were conducted and used for the bile analysis.","label":[],"Comments":[]}
{"id":3268,"text":"Feces samples were homogenized in 0.9% saline and then centrifuged at 13,000 rpm for 15 min to gather the feces homogenates (4 °C).","label":[],"Comments":[]}
{"id":3269,"text":"The protein precipitation and subsequent experimental methods of feces homogenates were in the same way as those of urine and applied for the feces analysis.","label":[],"Comments":[]}
{"id":3270,"text":"Seventy-two SD rats were applied to 4 experiments by collecting plasma, tissues, bile, urine and feces, respectively, to investigate the effects of A. Officinarum on systemic exposure, tissue distribution and excretion of indomethacin.","label":[[0,19,"Cohort"],[148,162,"Herb name"],[222,234,"Drug"]],"Comments":[]}
{"id":3271,"text":"Of them, eighteen rats were randomly divided into 3 groups (model, single- and multiple-dose groups of A. officinarum) with six rats in each group and applied to plasma experiment.","label":[[103,117,"Herb name"]],"Comments":[]}
{"id":3272,"text":"The rat gastric ulcer model was induced by indomethacin as described preciously [25].","label":[[8,21,"Pathology"],[43,56,"Drug"]],"Comments":[]}
{"id":3273,"text":"Briefly, indomethacin (20 mg\/kg of body weight) was orally administered to rats in the model group after 12 h of fasting.","label":[[9,22,"Drug"],[23,31,"Amount"]],"Comments":[]}
{"id":3274,"text":"The single-dose group of A. officinarum (S-AOE) was pretreated by oral administration of A. officinarum ethanol extract (0.18 g\/kg) once 30 min before receiving indomethacin (20 mg\/kg).","label":[[25,39,"Herb name"],[88,103,"Herb name"],[161,174,"Drug"],[174,183,"Amount"]],"Comments":[]}
{"id":3275,"text":"The multiple-dose group of A. officinarum (M-AOE) was pretreated once daily with A. officinarum extract (0.18 g\/kg) for 15 days and then indomethacin at an oral dosage of 20 mg\/kg body weight was given to rats 30 min after the end of the experimental period (15 days).","label":[[27,42,"Herb name"],[65,76,"Frequency"],[81,95,"Herb name"],[104,114,"Amount"],[120,127,"Duration"],[137,150,"Drug"],[171,180,"Amount"],[259,266,"Duration"]],"Comments":[]}
{"id":3276,"text":"And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group.","label":[],"Comments":[]}
{"id":3277,"text":"Serial blood samples were withdrawn from the orbital sinus into heparin-treated tubes under ether anaesthesia before dosing (0 min) and 0.167, 0.5, 1, 1.5, 2, 3, 5, 7, 9, 11 and 24 h after dosing.","label":[],"Comments":[]}
{"id":3278,"text":"Next, heparinized blood samples were centrifuged at 3000 rpm for 10 min at room temperature to obtain the plasma fractions.","label":[],"Comments":[]}
{"id":3279,"text":"Tissue experiment was performed by collecting the kidney, stomach, small intestine, large intestine, liver and spleen at 0.5, 1, 2, 4 and 6 h after administration.","label":[],"Comments":[]}
{"id":3280,"text":"These tissues were washed by cold 0.9% physiological saline (4 °C) and excess water was drained with filter paper.","label":[],"Comments":[]}
{"id":3281,"text":"Then tissue samples were accurately weighed and subjected to the processing described in the sample preparation section.","label":[],"Comments":[]}
{"id":3282,"text":"The whole procedures for treating rat tissues were carried out on the ice surface.","label":[],"Comments":[]}
{"id":3283,"text":"The rats in bile experiment were fixed on wooden plates and anesthetized with 3% pentobarbital sodium (0.15 mL\/100 g, i.p.).","label":[],"Comments":[]}
{"id":3284,"text":"Then rats’ abdomen was incised, and the common bile duct was cannulated with polyethylene tubing to collect the bile.","label":[],"Comments":[]}
{"id":3285,"text":"The bile was collected during 0–1 h, 1–2 h, 2–3 h, 3–4 h, 4–5 h, 5–6 h and 6–7 h after dosing.","label":[],"Comments":[]}
{"id":3286,"text":"In the course of bile collection, 1 mL of water was administered via the tail vein to the rats every 2 h. The rats in urine and feces experiment were kept separate in stainless steel metabolic cages.","label":[],"Comments":[]}
{"id":3287,"text":"Urine and feces were collected 0–6 h, 6–18 h and 18–28 h after administration.","label":[],"Comments":[]}
{"id":3288,"text":"Urine at each time point was centrifuged at 3000 rpm for 10 min and the supernatant was transferred into clean tubes.","label":[],"Comments":[]}
{"id":3289,"text":"All biological samples were frozen at −80 °C until assayed.","label":[],"Comments":[]}
{"id":3290,"text":"The method was fully validated in compliance with the U.S. Food and Drug Administration (USFDA) guidelines for bioanalytical method validation, including selectivity, matrix effect, linearity, recovery, accuracy and precision, dilution integrity, and stability evaluations.","label":[],"Comments":[]}
{"id":3291,"text":"Non-compartmental pharmacokinetic parameters of all the analytes in rat biological samples were calculated by DAS 3.0 software package (BioGuider Co., Shanghai, China).","label":[],"Comments":[]}
{"id":3292,"text":"All data obtained from this study were assumed to describe a normal standard distribution and are expressed as the mean ± standard deviation (SD), along with relative standard deviation (RSD).","label":[],"Comments":[]}
{"id":3293,"text":"Statistical analysis was performed using a one-way analysis of variance.","label":[],"Comments":[]}
{"id":3294,"text":"A value of P ≤ 0.05 was deemed to be statistically significant.","label":[],"Comments":[]}
{"id":3295,"text":"The cumulative excretion rates of indomethacin in bile and urine were calculated according to the following formula: cumulative excretion rate (%) = cumulative excretion\/administered dose × 100%.","label":[[4,30,"Parameter"],[34,47,"Drug"]],"Comments":[]}
{"id":3296,"text":"All tested analytes and IS were well separated with no significant endogenous or other interfering substances under the established UFLC-MS\/MS conditions.","label":[],"Comments":[]}
{"id":3297,"text":"Typical MS\/MS ion spectra of the protonated molecules ([M − H] Typical MS\/MS ion spectra of the protonated molecules ([M − H] Representative MRM chromatograms of indomethacin, NDI, ODI, IDAβG and IS in rat liver.","label":[[162,174,"Drug"]],"Comments":[]}
{"id":3298,"text":"(A) Blank liver samples, (B) blank liver samples spiked with four analytes and IS, and (C) liver samples at 30 min after oral administration of indomethacin solution (20 mg\/kg).","label":[[144,157,"Drug"],[167,175,"Amount"]],"Comments":[]}
{"id":3299,"text":"Calibration curves and LLOQs of indomethacin and its three metabolites in rat biological samples.","label":[],"Comments":[]}
{"id":3300,"text":"Pharmacokinetic (PK) parameters of indomethacin and its two metabolites in the model, S-AOE and M-AOE groups in rat plasma.","label":[[35,48,"Drug"]],"Comments":[]}
{"id":3301,"text":"Mean ± SD, n = 6.","label":[],"Comments":[]}
{"id":3302,"text":"∗P < 0.05 and ∗∗P < 0.01 versus mode group.","label":[],"Comments":[]}
{"id":3303,"text":"The validated method described herein was successfully applied to the pharmacokinetic study of indomethacin and its metabolites in rat plasma after oral administration of indomethacin with and without A. officinarum ethanol extract.","label":[[95,108,"Drug"],[171,184,"Drug"],[200,231,"Extraction process"],[201,215,"Herb name"]],"Comments":[]}
{"id":3304,"text":"Plasma samples were diluted 6-fold for analysis of ODI and NDI and 30-fold for analysis of indomethacin by reason of the high exposure concentration of indomethacin and its metabolites in rat plasma.","label":[[91,104,"Drug"],[152,165,"Drug"]],"Comments":[]}
{"id":3305,"text":"The plasma concentration-time curves of three analytes in model, S-AOE and M-AOE groups are presented in Fig.","label":[],"Comments":[]}
{"id":3306,"text":"3, and main pharmacokinetic parameters are summarized in Table 2.","label":[],"Comments":[]}
{"id":3307,"text":"Mean (±SD, n = 6) plasma concentration-time profiles of (A) indomethacin, (B) ODI and (C) NDI in the model, S-AOE and M-AOE groups in rat plasma.","label":[],"Comments":[]}
{"id":3308,"text":"Numerous studies have demonstrated that pharmacokinetic parameters, tissue distributions, and excretion could be altered by drug-drug, herb-drug or herb-herb interactions [8,9,[26], [27], [28], [29]].","label":[],"Comments":[]}
{"id":3309,"text":"Therefore, the protective effect of A. officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert.","label":[[36,50,"Herb name"],[54,66,"Drug"],[75,89,"Pathology"]],"Comments":[]}
{"id":3310,"text":"In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig.","label":[],"Comments":[]}
{"id":3311,"text":"3, but significant differences between AOE groups and model group in the pharmacokinetic parameters of indomethacin can be observed in Table 2.","label":[[103,116,"Drug"]],"Comments":[]}
{"id":3312,"text":"Pharmacokinetic parameters including maximum plasma concentration (C Since pharmacokinetic study results indicated that the method of multiple dosing was more effective, the tissue distribution and excretion experiments were not performed in a single-dose group.","label":[[37,65,"Parameter"],[174,208,"Parameter"]],"Comments":[]}
{"id":3313,"text":"Tissue distribution profiles of indomethacin and its three metabolites in the model and M-AOE groups are depicted in Fig. 4.","label":[[0,19,"Parameter"],[32,45,"Drug"]],"Comments":[]}
{"id":3314,"text":"Tissue distribution profiles of indomethacin and its three metabolites in the model and M-AOE groups.","label":[[32,45,"Drug"]],"Comments":[]}
{"id":3315,"text":"Tissue distribution results suggested that indomethacin was rapidly distributed into various tissues, including the kidney, stomach, small intestine, large intestine, liver and spleen, and mainly metabolized as the conjugated form, IDAβG, which principally existed in the small intestine following in the stomach, liver, kidney, spleen and large intestine in the model group.","label":[[43,56,"Drug"]],"Comments":[]}
{"id":3316,"text":"Interestingly, the concentration of indomethacin was almost unchanged in the small intestine in M-AOE group versus model group but the concentration of IDAβG was significantly decreased, which might be the cause that A. Officinarum promoted IDAβG metabolized into low molecular weight components by the gut flora or excreted in the bile.","label":[[36,49,"Drug"]],"Comments":[]}
{"id":3317,"text":"And A. Officinarum promoted the accumulation of indomethacin in the liver tissue 2 h after administration in the M-AOE group; thereby it benefited the metabolism of indomethacin by various metabolic enzymes.","label":[[4,18,"Herb name"],[48,61,"Drug"],[165,178,"Drug"]],"Comments":[]}
{"id":3318,"text":"However, the concentration of indomethacin in the stomach tissue was not reduced in M-AOE group compared with model group but its metabolites of ODI and IDAβG were significantly inhibited, indicating that indomethacin was metabolized less in the stomach and A. Officinarum was not by means of reducing the accumulation of indomethacin in stomach to exert gastrointestinal protection.","label":[[30,43,"Drug"],[205,218,"Drug"],[258,272,"Herb name"],[322,335,"Drug"]],"Comments":[]}
{"id":3319,"text":"Meanwhile, the concentration of indomethacin in the kindney tissue was decreased after A. officinarum treatment, suggesting that A. Officinarum did not act by promoting the excretion pathway of indomethacin in the urine.","label":[[32,45,"Drug"],[87,101,"Herb name"],[128,143,"Herb name"],[194,207,"Drug"]],"Comments":[]}
{"id":3320,"text":"In addition, the distributions of indomethacin and its metabolites in the large intestine tissue were all very little, and ODI in M-AOE group was significantly decreased, which might be also the effect of degradation of intestinal flora.","label":[[34,47,"Drug"],[205,236,"Pathology"]],"Comments":[]}
{"id":3321,"text":"The data in the spleen tissue were not changed statistically and the concentrations of all the analytes were very low.","label":[],"Comments":[]}
{"id":3322,"text":"Therefore, the protective effect of A. Officinarum on the gastrointestinal tract induced by indomethacin did not occur by reducing the accumulation of indomethacin in the target tissue, but might be through the degradation of the gut flora in the small intestine.","label":[[35,50,"Herb name"],[92,105,"Drug"],[151,164,"Drug"],[211,240,"Pathology"]],"Comments":[]}
{"id":3323,"text":"The cumulative excretion profiles of indomethacin and its three metabolites in bile, urine and feces of rats after oral administration in the model and M-AOE groups are presented in Fig. 5.","label":[[4,25,"Parameter"],[37,50,"Drug"]],"Comments":[]}
{"id":3324,"text":"(A) Biliary, (B) urinary and (C) fecal cumulative excretion profiles of indomethacin and its three metabolites after oral administration of 20 mg\/kg to rats in the model and M-AOE groups (n = 6).","label":[[0,60,"Parameter"],[72,85,"Drug"],[139,148,"Amount"]],"Comments":[]}
{"id":3325,"text":"Obviously, all analytes were excreted in the bile after 4 h of oral dosing in two experimental groups shown in Fig.","label":[],"Comments":[]}
{"id":3326,"text":"5A and the biliary cumulative excretion of IDAβG was highest compared with the excretions of all the analytes in the bile, urine and feces (52.82% in model group and 75.86% in M-AOE group within 7 h), indicating that parent drug indomethacin was mainly metabolized to the phase Ⅱ metabolite of IDAβG in the liver and excreted in the bile.","label":[[10,40,"Parameter"],[229,242,"Drug"]],"Comments":[]}
{"id":3327,"text":"Furthermore, we found that biliary excretions of indomethacin and its three metabolites in the M-AOE group were significantly more than that in model group, which suggested that co-administration of A. Officinarum contributed to increasing the excretions of indomethacin and its metabolites in the bile.","label":[[27,45,"Parameter"],[49,62,"Drug"],[258,271,"Drug"]],"Comments":[]}
{"id":3328,"text":"Moreover, the consistent results in Figs.","label":[],"Comments":[]}
{"id":3329,"text":"5B and C showed that urinary and fecal cumulative excretions of indomethacin and its three metabolites in M-AOE group were all larger than those in the model group except the excretion of indomethacin and ODI in the urine, which were coincident with tissue distribution results that indomethacin was less distributed in the kidney in M-AOE group versus model group.","label":[[21,61,"Parameter"],[64,76,"Drug"]],"Comments":[]}
{"id":3330,"text":"However, the urinary excretions of indomethacin and its metabolites in both experimental groups were very little (<2%), so that indomethacin was not primarily excreted in the urine.","label":[[13,31,"Parameter"],[35,48,"Drug"],[128,141,"Drug"]],"Comments":[]}
{"id":3331,"text":"From the above, the excretion study results indicated that indomethacin was principally excreted in the bile in the form of phase Ⅱ metabolite of IDAβG, and co-administration of A. Officinarum could facilitate the excretions of indomethacin and its three metabolites in the bile and feces of rats.","label":[[59,72,"Drug"],[177,192,"Herb name"],[228,241,"Drug"]],"Comments":[]}
{"id":3332,"text":"Therefore, one of the reasons for the gastrointestinal protection of A. Officinarum might promote excretion effects of indomethacin and its metabolites in the excretory system of rats.","label":[[69,83,"Herb name"],[119,132,"Drug"]],"Comments":[]}
{"id":3333,"text":"In summary, this study developed and validated a UFLC-MS\/MS method for simultaneous determination of indomethacin and its three metabolites and successfully applied it to comparative pharmacokinetic, tissue distribution and excretion studies to expound protective effect of A. officinarum against gastric injury induced by indomethacin in rats.","label":[[101,114,"Drug"],[274,288,"Herb name"],[297,311,"Pathology"],[323,335,"Drug"]],"Comments":[]}
{"id":3334,"text":"The results showed that co-administration of A. Officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin and reduced the systemic exposure and the retention time of indomethacin, and increased its elimination.","label":[[45,59,"Herb name"],[130,143,"Drug"],[203,215,"Drug"]],"Comments":[]}
{"id":3335,"text":"However, A. Officinarum did not act by reducing the accumulation of indomethacin in the target tissue of the stomach to exert gastrointestinal protection, but by promoting the excretions of indomethacin and its three metabolites including ODI, NDI and IDAβG in the bile and feces of rats, and thereby played a significant role in the gastroprotective effect.","label":[[9,23,"Herb name"],[68,81,"Drug"],[190,203,"Drug"]],"Comments":[]}
{"id":3336,"text":"The authors declare that there are no conflicts of interest.","label":[],"Comments":[]}
{"id":3337,"text":"The following is the Supplementary data to this article: This work was financially supported by the  Peer review under responsibility of Xi’an Jiaotong University.","label":[],"Comments":[]}
{"id":3338,"text":"Supplementary data to this article can be found online at","label":[],"Comments":[]}
